Member Event with Steve Bagshaw, Fujifilm Diosynth Biotechnologies

From their Billingham site, Fujifilm Diosynth Biotechnologies (FDB) utilise living cells and bacteria to produce complex biopharmaceutical drugs. The team also provide services to drug development companies worldwide, including the development of production processes created within their state-of-the-art laboratories.

Beginning as an offshoot from ICI/Zeneca in the nineties with a team of 20, FDB has grown dramatically into a pharmaceutical powerhouse with four global sites, >2000 staff, and revenues in excess of $500m.

Ensuring FDB's global vision, mission, and business objectives are met across four countries requires a strong and united leadership team. Heading FDB's operations is CEO Steve Bagshaw who has over 30 years’ experience in the UK and US with FDB and its predecessors. A visionary leader, since becoming CEO in 2014, Steve has led the company to new heights, resulting in FDB earning a reputation as a global leader in bio pharmaceuticals.

Dr Jen Vanderhoven (VP Global Business Change), Koen Hellendoorn (Director Strategic Business Development), Andy Topping (CSO), Mark Douglas (VP of Strategy), Simon Dewar (VP Process Development) and Paul Found (COO) also join Steve on the evening to delve deeper into FDB's business journey, including its growth pains and successes, and the ambitious plans the company has for our region.